Shanghai, China: WuXi STA, a subsidiary of WuXi AppTec, partnered with Multiply Labs to advance personalized pharmaceutical manufacturing. The collaboration focuses on deploying automated robotic systems capable of producing individualized medications.
The robotic technology enables manufacturing of advanced solid oral dosage forms, including capsules with personalized dosage strengths and multi-compartment capsules containing combinations of multiple active pharmaceutical ingredients. This addresses traditional manufacturing limitations where only one large batch could be produced at a time.
The system handles various formulation types (powders, blends, granules, beads, and minitabs) with preprogramming flexibility for different patient needs, dosage strengths, and release profiles. Applications target clinical and commercial production for pediatric, geriatric, and rare disease populations.
"This partnership demonstrates unprecedented speed in development and deployment toward enabling precision medicine to scale."
Fred Parietti, Co-Founder & CEO, Multiply Labs
"Automation is the future of pharmaceutical manufacturing. Combining robotic innovation with drug development expertise accelerates product development and ultimately expands patient access."
Jinling Chen, SVP, WuXi STA